Ones To Watch News
Refine Search
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. 13 November 2024
Biotechnology
Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. 13 November 2024
Biotechnology
Sino-American oncology company BeiGene has announced third-quarter 2024 financials, showing the total revenues was $1,002 million, up 28% compared to $781 million in the same period of 2023. 13 November 2024
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US subsidiary of Roche, of its decision to terminate the collaboration and licensing agreement for Nykode’s VB10.NEO cancer vaccine program. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
The combination of Merck & Co’s Keytruda (pembrolizumab) and Citius Pharmaceuticals’ Lymphir (denileukin diftitox-cxdl) showed promising preliminary results in an investigator-initiated Phase I clinical trial for cancer patients with recurrent solid tumors. 11 November 2024
Pharmaceutical
Aurinia Pharmaceuticals has announced a major strategic overhaul, reducing its workforce by almost half to focus on driving Lupkynis (voclosporin) growth. 11 November 2024
Biotechnology
Privately-held Boston-based biopharma FogPharma has announced a name change and unveiled a new AI-based platform. 11 November 2024
Pharmaceutical
Viracta Therapeutics has announced a significant restructuring to prioritize its lead oncology candidate, nana-val (valganciclovir/valganciclovir sodium), aimed at treating certain people with peripheral T-cell lymphoma (PTCL). 8 November 2024
Biotechnology
US biotech venture fund Aditum Bio and China’s Leads Biolabs today announced the formation of Oblenio Bio, marking the thirteenth company launched by Aditum. 7 November 2024
Biotechnology
Oncology-focused biotech company Tango Therapeutics announced an update on its PRMT5 program. Tango noted that, based on positive data from the dose escalation and early dose expansion cohorts of the TNG462 Phase I/II clinical trial, it has selected TNG462 to move forward into full development. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
PrognomiQ has announced a series D financing round of $34 million, led by Seer, bringing the firm’s total funding to over $135 million since its founding in September 2020. 6 November 2024
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) issued final guidance recommending reimbursement of Ayvakyt (avapritinib) from USA-based Blueprint Medicines. 6 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
Plus Therapeutics, an American firm advancing radiotherapeutics for central nervous system (CNS) cancers, has signed a new manufacturing services agreement with SpectronRx. 6 November 2024
Biotechnology
İş Private Equity - a subsidiary of Turkey's İşbank Group - has committed $39 million to a Harvard University research lab to launch Enlila, a biotech developing novel treatments for metabolic diseases. 20 June 2025
Pharmaceutical
Privately-held UK firm Cycle Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Harliku (nitisinone) tablets for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria (AKU). 20 June 2025
Pharmaceutical
Zealand Pharma, a Danish firm focused on the discovery and development of innovative peptide-based medicines, has announced positive topline results from part two of a Phase Ib multiple ascending dose (MAD) trial investigating 28 weeks of treatment with dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist. 20 June 2025
Biotechnology
Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies. 19 June 2025
Biotechnology
Scholar Rock has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug can reduce the amount of lean mass lost during weight reduction with Eli Lilly’s (NYSE: LLY) weight-loss drug Zepbound (tirzepatide). 19 June 2025
Pharmaceutical
Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership shake-up timed with a fresh $25 million financing round and a push to commercialize its lead eye implant therapy in the USA. 19 June 2025
Pharmaceutical
US biotech Actio Biosciences has raised $66 million in a series B round topport its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management. 19 June 2025
Biotechnology
SunRock Biopharma has teamed up with China’s Escugen to co-develop SRB123, a first-in-class antibody-drug conjugate (ADC) targeting CCR9, an antigen which is tied to particularly hard-to-treat cancers, including pancreatic, ovarian and lung. 18 June 2025
Biotechnology
Chinese biotech start-up BioTroy Therapeutics has raised over 200 million renminbi ($28 million) in series A financing to advance clinical trials for its experimental immunotherapy targeting CD3L1, a novel immune checkpoint aimed at tough-to-treat tumors. The company also plans to expand its early-stage pipeline and grow its Shanghai-based R&D team. 18 June 2025
Pharmaceutical
US biopharma Mineralys Therapeutics has announced positive top-line data from its Phase II Explore-CKD trial evaluating the safety and efficacy of 25mg of lorundrostat in subjects with hypertension and comorbid chronic kidney disease (CKD). 18 June 2025
Biotechnology
Cambridge, USA-based Immuneering Corporation late yesterday announced positive data from its ongoing Phase IIa clinical trial evaluating atebimetinib (IMM-1-104), an oral, once-daily novel MEK inhibitor, in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients. 18 June 2025
Pharmaceutical
Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric diseases, today launched from stealth having raised a total of $140 million (£107 million) in the last nine months. 18 June 2025
Pharmaceutical
US pharma firm Lisata Therapeutics has teamed up with tech-bio company GATC Health in a strategic alliance aimed at using artificial intelligence to streamline drug development and improve success rates. 18 June 2025
Biotechnology
US biotech Dyne Therapeutics has revised its regulatory approach for DYNE-101, a treatment in development for myotonic dystrophy type 1 (DM1), after discussions with the American medicines regulator. 18 June 2025
Biotechnology
Shares of USA-based NextCure slumped 26% to $0.50 on Monday, after the company announced a strategic partnership with China-based Simcere Zaiming, subsidiary of Simcere Pharmaceutical Group Ltd to develop a therapy for the treatment of solid tumors. 17 June 2025
Biotechnology
Cambridge, UK-based Maxion Therapeutics today announced the appointment of Dr Stefan Härtle as chief development officer, effective immediately. 17 June 2025
Pharmaceutical
Supernus Pharmaceuticals is to buy Sage Therapeutics for total consideration of around $795 million. 16 June 2025
Pharmaceutical
French drug developer Averoa today announced that the European Commission (EC) has granted marketing authorization for Xoanacyl (ferric citrate coordination complex). 16 June 2025
Biotechnology
Boston, USA-based biotech Solu Therapeutics today announced the appointment of Enda Moran as chief operating officer (COO). 16 June 2025
Biotechnology
Californian biotech Jasper Therapeutics presented data from the 180mg cohort of the company’s SPOTLIGHT Phase Ib/IIa study of subcutaneous briquilimab in adult participants with chronic inducible urticaria (CIndU) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. 16 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze